BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31220400)

  • 1. The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer.
    Bartkowiak D; Siegmann A; Böhmer D; Budach V; Wiegel T
    BJU Int; 2019 Nov; 124(5):785-791. PubMed ID: 31220400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
    Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
    Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
    Bottke D; Bartkowiak D; Siegmann A; Thamm R; Böhmer D; Budach V; Wiegel T
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):344-349. PubMed ID: 30487644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.
    Budäus L; Schiffmann J; Graefen M; Huland H; Tennstedt P; Siegmann A; Böhmer D; Budach V; Bartkowiak D; Wiegel T
    Strahlenther Onkol; 2017 Sep; 193(9):692-699. PubMed ID: 28470414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
    BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
    Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
    Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.
    Taylor N; Kelly JF; Kuban DA; Babaian RJ; Pisters LL; Pollack A
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):755-63. PubMed ID: 12788182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer.
    Bartkowiak D; Thamm R; Siegmann A; Böhmer D; Budach V; Wiegel T
    Radiother Oncol; 2021 Jan; 154():255-259. PubMed ID: 32920006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
    Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy.
    Milonas D; Laenen A; Venclovas Z; Jarusevicius L; Devos G; Joniau S
    Clin Transl Oncol; 2022 Feb; 24(2):371-378. PubMed ID: 34453699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
    Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.
    Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T
    Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study.
    Mizowaki T; Aoki M; Nakamura K; Yorozu A; Kokubo M; Karasawa K; Kozuka T; Nakajima N; Sasai K; Akimoto T
    J Radiat Res; 2015 Jul; 56(4):750-6. PubMed ID: 25910489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival.
    Casas F; Valduvieco I; Oses G; Izquierdo L; Archila I; Costa M; Cortes KS; Barreto T; Ferrer F
    Clin Transl Oncol; 2019 Mar; 21(3):355-362. PubMed ID: 30128953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results.
    Lohm G; Bottke D; Jamil B; Miller K; Neumann K; Bartkowiak D; Hinkelbein W; Wiegel T
    World J Urol; 2013 Apr; 31(2):423-8. PubMed ID: 22460203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis.
    Fossati N; Parker WP; Karnes RJ; Colicchia M; Bossi A; Seisen T; Di Muzio N; Cozzarini C; Noris Chiorda B; Fiorino C; Gandaglia G; Bartkowiak D; Wiegel T; Shariat S; Goldner G; Battaglia A; Joniau S; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A; Boorjian SA
    Eur Urol; 2018 Aug; 74(2):134-137. PubMed ID: 29544737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.